Eton Reports FDA Application Submission for ET-900 Phase 2 Spasm Trial

• Eton Pharmaceuticals announced an FDA investigational new drug application submission for a Phase 2 trial of ET-900, targeting refractory epileptic spasms.
• The University of Chicago-sponsored study targets up to 20 patients aged 2-18; initial dosing is planned for the first quarter of 2027.
• Eton retains commercial rights to ET-900 under a patent license from Baylor College of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-034277), on November 02, 2026, and is solely responsible for the information contained therein.